Core Insights - Foghorn Therapeutics is hosting a virtual investor event on October 30, 2025, to discuss updates on its Selective ARID1B, Selective CBP, and Selective EP300 degrader programs [1][3] - The company will present significant progress on its Selective ARID1B degrader program at the TPD and Induced Proximity Summit, highlighting its potential for treating endometrial, gastric, and bladder cancers [2] Company Overview - Foghorn Therapeutics is focused on discovering and developing a novel class of medicines that target genetically determined dependencies within the chromatin regulatory system [4] - The company utilizes its proprietary Gene Traffic Control platform to systematically study and validate potential drug targets within this system, with multiple product candidates in oncology [4] Event Details - The Keynote Plenary session will feature a presentation titled "Harnessing Degradation to Achieve Selectivity & First-in-Class Targeting of Challenging Chromatin Regulatory Proteins" on October 29, 2025 [3] - The virtual investor event will provide pipeline updates and will be accessible via the company's website after the conference [3]